Bayer and Recursion focus research collaboration on Oncology
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
US business grew by +12.8% YoY
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated